ImmunOs Therapeutics receives 71 million Swiss francs

Based in Schlieren, ImmunOs Therapeutics has raised investment equivalent to 71 million francs in a Series B funding round. The round was led by experienced North American biotech investors Samsara Biocapital, Lightspeed Venture Partners and Gimv. “The raise underlines our promising, first-in-class immunotherapy approach for the treatment of both solid and liquid tumors,” said ImmunOs CEO Sean R. Smith in a press release.

The company, which is in the portfolio of venture capital firm Redalpine Venture Partners, is developing the next generation of novel immunotherapies that target the innate immune system. ImmunOs will use these proceeds to fund the development of its lead candidate through Phase 2 clinical trials. According to the press release, this is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets key components of the innate immune system.

A Phase 1 clinical trial is planned to start in the second half of 2022. Additionally, ImmunOs has established a U.S. subsidiary to further expand its international reach and execute future U.S. clinical trials.

In connection with the financing, ImmunOs has added three new members to its Board of Directors: Shelley Chu from Lightspeed, Marcos Milla from Samsara and Andreas Jurgeit, a Partner at Gimv.

ImmunOs Therapeutics AG is a spin-off from the University of Zurich (UZH) and the University of Basel with headquarters in the Bio-Technopark Schlieren-Zurich. mm